-
Product Insights
Net Present Value Model: Perseris
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Perseris Drug Details Risperidone (Perseris) is...
-
Product Insights
Net Present Value Model: Sublocade
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Sublocade Drug Details Buprenorphine (Sublocade, Subutex)...
-
Product Insights
Net Present Value Model: Suboxone
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Suboxone Drug Details Buprenorphine hydrochloride and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – INDV-2000
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry INDV-2000 Drug Details INDV-2000 is under development for the treatment of nicotine addiction and...
-
Product Insights
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Orexin Receptor Type 1 – Drugs In Development, 2022, outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Orexin Receptor Type 1 (Hypocretin...
-
Product Insights
Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Opium (Opioid) Addiction develops after using opioids regularly for a period. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). Its signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping, and pain in the bones. The predisposing factors include age, personal history/ family history of substance abuse, cigarette dependency, and psychological stress. The Opium...
-
Product Insights
Opium (Opioid) Addiction Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The Opium (Opioid) Addiction clinical trial market research report provides an overview of the Opium (Opioid) Addiction clinical trials scenario. The report provides top-line data relating to the clinical trials on Opium (Opioid) Addiction. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Alcohol Addiction – Global Clinical Trials Review, 2022
The alcohol addiction clinical trial report provides a comprehensive overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on number of ongoing trials).
-
Product Insights
Opium Withdrawal Syndrome Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Opium Withdrawal Syndrome Global Clinical Trials Review, H1, 2018" provides an overview of Opium Withdrawal Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Opium Withdrawal Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Drug Addiction Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Drug Addiction Global Clinical Trials Review, H1, 2019" provides an overview of Drug Addiction clinical trials scenario. This report provides top line data relating to the clinical trials on Drug Addiction. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...